Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
On November 16, 2026, Lexeo Therapeutics reported positive interim results from HEROIC-PKP2, its Phase I/II trial of LX2020, a one-time gene therapy for arrhythmogenic cardiomyopathy (ACM) caused by mutations in the PKP2 gene. At the higher dose, dangerous runs of extra heartbeats fell by an average of 80%, and heart biopsies showed the missing protein coming back.
Lexeo also said the FDA is open to using these heart-rhythm events as the main measure for a possible accelerated approval, and it plans to settle the design of a pivotal study in the first half of 2027.

The patients this is for
ACM is an inherited heart muscle disease. Heart muscle cells are held together by junctions called desmosomes, and PKP2 (plakophilin-2) is one of the proteins that builds them. When one copy of PKP2 is faulty, the junctions weaken, heart muscle is slowly replaced by scar and fat, and the heart becomes prone to fast, irregular rhythms.
The disease often shows up in young adults, sometimes as fainting, palpitations or sudden cardiac arrest during exercise. Treatment today manages the risk: activity limits, heart-rhythm drugs, ablation procedures and an implanted defibrillator. None of these fix the missing protein. PKP2 mutations cause about half of all ACM, which Lexeo estimates affects about 60,000 people in the US.
How LX2020 works
LX2020 uses an AAVrh10 viral vector to deliver a working copy of the PKP2 gene to heart cells in a single intravenous infusion. The goal is to raise PKP2 protein levels enough to strengthen the cell junctions and calm the heart's rhythm.
The interim results
The trial has treated 10 adults: 3 at a lower dose (2×10^13 vg/kg) and 7 at a higher dose (6×10^13 vg/kg). As of the October 15, 2026 data cutoff, 9 of the 10 had at least 12 months of follow-up.
In the high-dose group:
Non-sustained ventricular tachycardia (NSVT), short runs of a dangerously fast heartbeat, fell by an average of 80%, and 6 of 7 participants improved.
Premature ventricular contractions (PVCs), single extra beats, fell by an average of 44%, with 5 of 7 improving.
5 of 7 reported feeling better overall on a standard patient questionnaire.
Cardiac MRI showed heart structure and function were stable or improved.
Heart biopsies showed dose-dependent increases in PKP2 RNA and PKP2 protein, which suggests the new gene is being read and used in heart tissue.

Safety
Lexeo reported no clinically significant activation of complement, an immune response that has caused serious problems with some high-dose AAV therapies. No one stopped the study. Rises in liver tests were reported and were manageable. One participant had a serious episode of ventricular tachycardia, a Grade 3 event, three months after dosing.
What to watch
LX2020 has the FDA's RMAT, Orphan Drug and Fast Track designations. Lexeo said the FDA is open to using NSVT as a surrogate primary endpoint for accelerated approval. The company plans to align on a pivotal study design in the first half of 2027 and start that study in the second half of 2027.
Ten patients is a small group, and heart rhythms naturally vary over time, so a larger, controlled study will be needed to confirm the benefit. The biopsy results are an important early signal, because they tie the clinical changes to the protein the therapy is meant to restore. Read our explainer on why an AAV gene therapy can raise long-term safety questions.
The bottom line
In a small early trial, a one-time AAV gene therapy for PKP2 heart disease cut dangerous heart-rhythm events by 80% on average at the higher dose and restored PKP2 protein in heart tissue. With the FDA open to a faster approval path, LX2020 could become one of the first gene therapies for an inherited heart rhythm disease.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times




Comments